ALBANY, N.Y. – August 6, 2014 – Albany College of Pharmacy and Health Sciences (ACPHS) announced today that Thomas D’Ambra, Ph.D., co-founder of Albany Molecular Research Inc. (NASDAQ: AMRI), has been appointed to the College’s Board of Trustees.
Dr. D’Ambra co-founded Albany Molecular Research, Inc. (AMRI) in 1991 and served as the company’s President and Chief Executive Officer until his retirement in 2013. He is currently Chairman of the Board at AMRI.
Headquartered in Albany, NY, Albany Molecular Research Inc. developed the active ingredient in the allergy medication Allegra. Today, AMRI is a global contract research and manufacturing organization with locations in North America, Europe, and Asia.
Dr. D'Ambra was responsible for much of the company’s growth through the years, playing key roles in all aspects of AMRI’s business, including bench research, business development, and operational and strategic management.
“As he demonstrated so clearly with AMRI, Tom is a talented chemist, innovator, entrepreneur, and businessman,” said Gregory Dewey, Ph.D., President of Albany College of Pharmacy and Health Sciences. “Both the Board of Trustees and the College will benefit greatly from his knowledge and expertise. We are excited to welcome him as a trustee.”
About Albany College of Pharmacy and Health Sciences
Founded in 1881, Albany College of Pharmacy and Health Sciences is a private, independent institution with a long tradition of academic and research excellence. The College is committed to educating the next generation of leaders in the health care professions and advancing innovative research that translates scientific discoveries into therapies that benefit humankind. In addition to its doctor of pharmacy program, ACPHS offers six bachelor’s programs and five graduate programs in the health sciences. The College’s main campus is located in Albany, New York; its satellite campus is in Colchester, Vermont.